Unleash Immuno Oncolytics is developing UIO-524, an armed oncolytic virus that selectively targets both malignant and stromal cells within tumors, utilizing conditionally replicating viruses and virally produced cytokines to enhance the immune response. This approach addresses the challenge of metastatic disease by disrupting tumor architecture and altering the tumor microenvironment, enabling the body to more effectively eliminate cancer cells.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OBFounders
Product
Problem
Metastatic cancers present a significant challenge due to their location within the body and the protective stroma that shields malignant cells from therapeutic interventions. This dense connective tissue fosters cancer dissemination and allows cancer cells to evade even advanced treatments.
Solution
Unleash Immuno Oncolytics is developing UIO-524, an armed oncolytic virus designed to target both malignant and stromal cells within tumors. The conditionally replicating virus selectively infects tumor cells and replicates within the stroma, physically disrupting the tumor architecture and altering the tumor microenvironment. This approach, combined with virally produced cytokines, modulates the body's immune defenses, enhancing the natural ability to eliminate malignant cells and fostering a systemic immune response.
Target Audience
The primary target audience includes oncology researchers and clinicians focused on developing novel immunotherapies for metastatic cancers, as well as pharmaceutical companies specializing in oncolytic virus-based treatments.
Features
- Conditionally replicating virus selectively targets both malignant and stromal cells.
- Virus replicates within the stroma to disrupt tumor architecture.
- Armed with multiple cytokines to modulate the immune system.
- Designed to facilitate infection throughout the entire tumor mass.
- Aims to unleash a systemic immune response.